Breast cancer patients with oestrogen receptor positive tumours are treated with endocrine (hormonal) therapy. However, resistance to endocrine therapy is a major problem. In this video, PhD student Daniel Vilar Jorge explains why scientists from the international research consortium EpiPredict are focusing on this urgent problem by studying the role of 'epigenetics'.
The mission of EpiPredict is to train a group of young researchers in a new approach to fully exploit the epigenetics of resistance to therapy in Estrogen Receptor positive (ER+) breast cancer.
This video was made by EpiPredict fellows Dan Vilar Jorge (Imperial College London), Giacomo Corleone (Imperial College London), Rohit Bharat (Università di Milano Bicocca) and Mihály Koncz (Hungarian Academy of Sciences) in collaboration with EpiPredict Partner Organisation Science Matters (www.science-matters.eu). The video was publicly presented for the first time during an EpiPredict Science Cafe organised in Heidelberg (2017).
Watch the video here.